Line-1 inhibitors to treat cns and systemic diseases
OwnerEckard WEBER, Michael G. CORDINGLEYinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating or preventing a CNS or systemic disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a LINE-1 inhibitor, or a pharmaceutical composition thereof.
Claims26
A method of treating or preventing a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a LINE-1 inhibitor, or a pharmaceutical composition thereof, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,
10-12. (canceled)
14-16. (canceled)
(canceled)
A kit comprising a LINE-1 inhibitor, or a pharmaceutical composition thereof, and instructions of administering the LINE-1 inhibitor, or pharmaceutical composition thereof, to a subject having a disease, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,
(canceled)
(canceled)
26-28. (canceled)
Dependencies are inferred from the claim text.